drugset / Trial / NCT01895569
Triple Therapy in Type 2 Diabetic Patients
Phase 4
Unknown
64 enrolled
University of Pavia
Fondazione IRCCS Policlinico San Matteo di Pavia · collab
NaSingle-groupOpen-labelTreatment
Summary
The treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic agents to reach the adequate glycemic control. The aim of the study is to evaluate the effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic variability compared to metformin monotherapy, and compared to a combination of metformin and pioglitazone. To assess glycemic variability a continuous glucose monitoring system will be used.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | — |
| Subject | Pioglitazone | Small molecule | 15 mg | — |
| Subject | Sitagliptin | Small molecule | 100 mg | — |